FACULTY
|
Co-chairs
|
|
|
Brett King, MD
Associate Professor of Dermatology Yale University School of Medicine New Haven, Connecticut |
Rodney Sinclair MD, MBBS, FACD
Professor of Medicine University of Melbourne Director of Dermatology, Epworth Health Care Director Sinclair Dermatology East Melbourne, Australia |
|
Program content was co-created by Dr. Brett King and Dr. Rodney Sinclair
|
|
|
Speaking Faculty
|
|
|
Antonella Tosti, MD
Fredric Brandt Endowed Professor of Dermatology Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami, Florida |
|
PROGRAM OVERVIEW
This enduring, case-based activity targets health care gaps related to the underlying autoimmune causes of alopecia areata (AA) and targeted treatment approaches, which can have a profound impact on health-related quality of life through burden of disease and associated comorbidities.
- By addressing these gaps, you can assess whether your approach to AA management using immune-related targeted treatment approaches and comorbidity assessment could be modified to help close these gaps.
- Expert discussion will guide you in analyzing and identifying appropriate candidates for immune-targeted treatment of alopecia with JAK inhibitors, as well as assessment and management strategies for associated comorbidities.
- You will also be immersed in dynamic animations using a whiteboard platform to memorably highlight key points related to immune pathways in the development of alopecia areata and patient counseling techniques for tailored disease and comorbidity management.
TARGET AUDIENCE
This enduring educational activity is intended for dermatology professionals who care for patients with AA.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Elucidate the immune pathways involved in the pathogenesis of AA and their implications for targeted treatment
- Identify patients in practice who may potentially benefit from JAK inhibitors for treating AA based on clinical trial data on their safety and efficacy
- Select optimal approaches for identifying and addressing the physical and psychological comorbidities of AA
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in caring for patients with AA.
Credit: 1.0 ANCC Contact Hour
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Faculty | Relationship | Manufacturer |
|---|---|---|
| Brett King, MD | Speakers bureau | Regeneron and Sanofi Genzyme |
| Consultant | Aclaris Therapeutics, Almirall, Arena Pharmaceuticals, Bristol-Meyers Squibb Company, Concert Pharmaceuticals, Dermavant Sciences, Eli Lilly, Pfizer, and Viela Bio | |
| Clinical trial investigator | Arena Pharmaceuticals, Concert Pharmaceuticals, Eli Lilly, NIH, and Pfizer | |
| Rodney Sinclair MD, MBBS, FACD | Speakers bureau | Pfizer and Eli Lilly |
| Consultant/Advisory Board | Pfizer, Eli Lilly | |
| Clinical Investigator | Pfizer, Eli Lilly, LEO Pharma, Gaderma, Reistone | |
| Antonella Tosti, MD | Consultant | DS Laboratories, Monat Global, Almirall, Tirthy Madison, Lilly, Leo Pharmaceuticals, Bristol-Myers Squibb, and P&G |
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring virtual activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the pre- and post-test and evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: June 16, 2021
EXPIRATION DATE: June 16, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
